Three reviews show when changes happened and why testing conditions matter. Follow the LDL, liver-marker and biological-age results across the full record.
P.F., male, 40, was followed from May 2025 to April 2026, approximately 11 months. The record includes results from May 2025, February 2026 and April 2026. LDL fell from 105 to 78 mg/dL across the full period. His PhenoAge score fell from 37 to 31 years and remained at 31 across the February and April reviews; KDM-13 fell from 36.5 to 26.0 years.
Three panels reveal more than a headline
P.F.’s liver enzymes rose at the middle review before falling at the last. The recorded panels let readers see that sequence, while the meal and infection notes explain why some metabolic readings need extra context. That is the practical value of tracking a pattern over time.
Starting point and context
The case describes a personalised diet, structured training and oral supplementation. The three reported panels show why the starting point matters: ALT was 31 U/L in May, rose to 57 in February and was 27 in April; AST was 27, then 49, then 32 U/L.
Explore EVA blood biomarker testing
The recorded results
| Biomarker | May 2025 | Feb 2026 | Apr 2026 |
|---|---|---|---|
| Cardiovascular & Lipids | |||
| LDL (mg/dL) | 105 (H) | 122 (H) | 78 |
| ApoB (mg/dL) | 72 | 83 | 70 |
| HDL (mg/dL) | 46.8 | — | Improving |
| TG/HDL ratio | Elevated† | — | <2.0 |
| hs-CRP (mg/L) | 0.34 | 0.24 | 0.34 |
| Liver Enzymes | |||
| ALT (U/L) | 31 | 57 (H) | 27 |
| AST (U/L) | 27 | 49 (H) | 32 |
| Metabolic | |||
| Fasting Insulin (µIU/mL) | 10.85 | 4.24 | 8.21† |
| HOMA-IR | — | 0.93 | 1.62† |
| Nutrition & Methylation | |||
| Folate (ng/mL) | 9.43 | — | Improved |
| Homocysteine (µmol/L) | 12.4 | Improving | Improving |
| Vitamin D (ng/mL) | 39.05 | — | ~50 |
| Vitamin B12 (pg/mL) | 772 | — | Optimal |
| Biological Age | |||
| KDM-13 Biological Age | 36.5 yrs | — | 26.0 yrs |
| PhenoAge | 37 yrs | 31 yrs | 31 yrs |
Figures are reproduced from the case record, including qualitative entries and reported percentage changes. Source labels such as optimal describe the case’s interpretation, not a universal reference range. A dash indicates a value not supplied.
Context that matters
- The May 2025 triglyceride result was 417 mg/dL from a postprandial, non-fasting sample. The chart shows approximately 90 mg/dL in April; the shared summary describes it as below 90 mg/dL. No exact April value is supplied. These are not a like-for-like fasting comparison; no precise percentage reduction is claimed here.
- The source estimates that the baseline fasting-equivalent triglyceride value would have been lower but still elevated; it provides no measured fasting baseline or numerical conversion.
- The April 2026 insulin result of 8.21 µIU/mL and HOMA-IR of 1.62 followed a late meal at approximately 1am and an active infection. The source identifies February’s HOMA-IR of 0.93 as the cleaner metabolic datapoint.
- ApoB was 72, 83 and 70 mg/dL across the three panels, broadly stable from first to last. The source records approximately 60% adherence to the berberine/bergamot combination and plans for more consistent use.
- April vitamin D is approximate at ~50 ng/mL. Some follow-up fields are qualitative rather than numerical; no missing values have been inferred.
The recorded protocol
The following items are recorded in this person’s plan. This is a historical description, not a protocol for readers to copy.
- Berberine (ApoB, LDL, metabolic)
- Omega-3 3 softgels daily (triglycerides, inflammation)
- L-Methylfolate sublingual
- B12 Methylcobalamin sublingual
- Vitamin D3+K2 drops
- Magnesium Bisglycinate
- Zinc Bisglycinate + Copper
- DNA-directed personalised diet (fat type, protein sources)
- Structured training programme
- 2× salmon/week (Omega-3 dietary support)
Learn about personalised supplements
What remained in progress
ApoB remained a follow-up priority despite the LDL change. The record also identified cardiovascular training as a focus for HDL. This case is useful because it shows a changing trajectory across several tests, including temporary rises and sampling conditions that affect interpretation.
Reading the biological-age result
Biological-age scores are model outputs derived from the inputs available to that model. A lower score is not a measured gain in lifespan. Different models use different inputs and should be labelled and interpreted separately.
Why is there no triglyceride percentage headline?
The baseline was non-fasting and the follow-up figure is approximate. Showing those conditions alongside the readings gives a more useful account than presenting a precise, like-for-like reduction.
How this connects to EVA
EVA connects blood testing, clinician-reviewed personalised supplements and follow-up. Blood Intelligence uses your blood results; Elite DNA + Blood adds genetic information. DNA is optional. The aim is a personal plan grounded in your information, with review as new results become available.
Give future results a baseline to compare with
If you want to understand how your markers change over time, the starting point is a documented baseline and a plan for interpreting later results.
See how to start with EVAExplore blood testing, optional DNA and personalised supplements, with the current steps to get started in Dubai.
This is an individual observational case, not a controlled trial. Biomarker changes and biological-age scores do not establish the effect of a particular supplement, predict an individual’s lifespan or guarantee future results. The protocol described was personalised and is not a recommendation to self-prescribe. EVA supports informed health decisions and is not intended to diagnose, treat, cure or prevent disease. Consult a qualified healthcare provider for medical advice.
Source: EVA clinical case record supplied for publication. Observation dates and model names are shown in the case. Prepared for web publication in October 2026.